Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.38 USD | +3.68% | -5.90% | +174.97% |
10/05 | Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating | MT |
09/05 | Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+174.97% | 223.56Cr | |
+27.74% | 4.92TCr | |
+0.73% | 4.21TCr | |
+50.47% | 4.04TCr | |
-5.26% | 2.89TCr | |
+13.57% | 2.61TCr | |
-22.52% | 1.87TCr | |
+7.93% | 1.33TCr | |
+32.27% | 1.23TCr | |
-0.18% | 1.2TCr |
- Stock Market
- Equities
- VERA Stock
- News Vera Therapeutics, Inc.
- Oppenheimer Raises Vera Therapeutics Price Target to $34 From $26, Maintains Outperform Rating